Autophagic action of new targeting agents in head and neck oncology

Cancer Biology and Therapy

Volumn 13, Issue 11, 2012, Pages 978-991

  Rikiishi, Hidemi ^a  

^a TOHOKU UNIVERSITY   (Japan)

Author keywords

Apoptosis; Autophagic cell death; Autophagic resistance; Autophagy; Epidermal growth factor; Head and neck squamous cell carcinoma; Molecular targeted agents

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; ANTINEOPLASTIC AGENT; BGT 226; BORTEZOMIB; CETUXIMAB; CHLOROQUINE; CISPLATIN; DASATINIB; DOCETAXEL; DOXORUBICIN; EC 5; ERLOTINIB; ETOPOSIDE; EVEROLIMUS; FLUOROURACIL; GEFITINIB; GEMCITABINE; IRINOTECAN; KU 363; LAPATINIB; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; RAPAMYCIN; SARACATINIB; SORAFENIB; SUNITINIB; TANESPIMYCIN; TEMSIROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VORINOSTAT;

ANTINEOPLASTIC ACTIVITY; AUTOPHAGY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CELL CYCLE ARREST; CELL SURVIVAL; CHEMORADIOTHERAPY; CLINICAL TRIAL (TOPIC); DRUG MEGADOSE; DRUG POTENTIATION; DRUG TREATMENT FAILURE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTINEOPLASTIC AGENTS; AUTOPHAGY; CARCINOMA, SQUAMOUS CELL; HEAD AND NECK NEOPLASMS; HUMANS; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84865836586     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.21079     Document Type: Review

References (89)

1. Fury MG, Pfister DG. Current recommendations for systemic therapy of recurrent and/or metastatic head and neck squamous cell cancer. J Natl Compr Canc Netw 2011; 9:681-9; PMID:21636539.
2. Kondo Y, Kanzawa T, Sawaya R, Kondo S. The role of autophagy in cancer development and response to therapy. Nat Rev Cancer 2005; 5:726-34; PMID:16148885; http://dx.doi.org/10.1038/nrc1692.
3. Moscat J, Diaz-Meco MT. p62 at the crossroads of autophagy, apoptosis and cancer. Cell 2009; 137:1001-4; PMID:19524504; http://dx.doi.org/10.1016/j.cell. 2009.05.023.
4. Chaachouay H, Ohneseit P, Toulany M, Kehlbach R, Multhoff G, Rodemann HP. Autophagy contributes to resistance of tumor cells to ionizing radiation. Radiother Oncol 2011; 99:287-92; PMID:21722986; http://dx.doi.org/10.1016/j. radonc.2011.06.002.
5. Xie BS, Zhao HC, Yao SK, Zhuo DX, Jin B, Lv DC, et al. Autophagy inhibition enhances etoposide-induced cell death in human hepatoma G2 cells. Int J Mol Med 2011; 27:599-606; PMID:21274505.
6. Ren JH, He WS, Nong L, Zhu QY, Hu K, Zhang RG, et al. Acquired cisplatin resistance in human lung adenocarcinoma cells is associated with enhanced autophagy. Cancer Biother Radiopharm 2010; 25:75-80; PMID:20187799; http://dx.doi.org/10.1089/cbr.2009.0701.
7. Shimizu S, Kanaseki T, Mizushima N, Mizuta T, Arakawa-Kobayashi S, Thompson CB, et al. Role of Bcl-2 family proteins in a non-apoptotic programmed cell death dependent on autophagy genes. Nat Cell Biol 2004; 6:1221-8; PMID:15558033; http://dx.doi.org/10.1038/ncb1192.
8. Henson ES, Gibson SB. Surviving cell death through epidermal growth factor (EGF) signal transduction pathways: implications for cancer therapy. Cell Signal 2006; 18:2089-97; PMID:16815674; http://dx.doi.org/10.1016/j.cellsig. 2006.05.015.
9. Leemans CR, Braakhuis BJ, Brakenhoff RH. The molecular biology of head and neck cancer. Nat Rev Cancer 2011; 11:9-22; PMID:21160525; http://dx.doi.org/10.1038/nrc2982.
10. Weihua Z, Tsan R, Huang WC, Wu Q, Chiu CH, Fidler IJ, et al. Survival of cancer cells is maintained by EGFR independent of its kinase activity. Cancer Cell 2008; 13:385-93; PMID:18455122; http://dx.doi.org/10.1016/j.ccr.2008.03. 015.
11. Pedrero JM, Carracedo DG, Pinto CM, Zapatero AH, Rodrigo JP, Nieto CS, et al. Frequent genetic and biochemical alterations of the PI 3-K/AKT/PTEN pathway in head and neck squamous cell carcinoma. Int J Cancer 2005; 114:242-8; PMID:15543611; http://dx.doi.org/10.1002/ijc.20711.
12. Nathan CO, Amirghahari N, Rong X, Giordano T, Sibley D, Nordberg M, et al. Mammalian target of rapamycin inhibitors as possible adjuvant therapy for microscopic residual disease in head and neck squamous cell cancer. Cancer Res 2007; 67:2160-8; PMID:17332346; http://dx.doi.org/10.1158/0008-5472.CAN-06-2449.
13. Chang KY, Tsai SY, Wu CM, Yen CJ, Chuang BF, Chang JY. Novel phosphoinositide-3-kinase/mTOR dual inhibitor, NVP-BGT226, displays potent growth-inhibitory activity against human head and neck cancer cells in vitro and in vivo. Clin Cancer Res 2011; 17:7116-26; PMID:21976531; http://dx.doi.org/10. 1158/1078-0432.CCR-11-0796.
14. Hegymegi-Barakonyi B, Eros D, Szántai-Kis C, Breza N, Bánhegyi P, Szabó GV, et al. Tyrosine kinase inhibitors - small molecular weight compounds inhibiting EGFR. Curr Opin Mol Ther 2009; 11:308-21; PMID:19479664.
15. Wakeling AE, Guy SP, Woodburn JR, Ashton SE, Curry BJ, Barker AJ, et al. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 2002; 62:5749-54; PMID:12384534.
16. Sirotnak FM, Zakowski MF, Miller VA, Scher HI, Kris MG. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 2000; 6:4885-92; PMID:11156248.
17. Pernas FG, Allen CT, Winters ME, Yan B, Friedman J, Dabir B, et al. Proteomic signatures of epidermal growth factor receptor and survival signal pathways correspond to gefitinib sensitivity in head and neck cancer. Clin Cancer Res 2009; 15:2361-72; PMID:19318490; http://dx.doi.org/10.1158/1078-0432. CCR-08-1011.
18. Cheng Y, Zhang Y, Zhang L, Ren X, Huber-Keener KJ, Liu X, et al. MK-2206, a novel allosteric inhibitor of Akt, synergizes with gefitinib against malignant glioma via modulating both autophagy and apoptosis. Mol Cancer Ther 2012; 11:154-64; PMID:22057914; http://dx.doi.org/10.1158/1535-7163.MCT-11-0606.
19. Han W, Pan H, Chen Y, Sun J, Wang Y, Li J, et al. EGFR tyrosine kinase inhibitors activate autophagy as a cytoprotective response in human lung cancer cells. PLoS One 2011; 6:18691; PMID:21655094; http://dx.doi.org/10.1371/journal. pone.0018691.
20. Brehmer D, Greff Z, Godl K, Blencke S, Kurtenbach A, Weber M, et al. Cellular targets of gefitinib. Cancer Res 2005; 65:379-82; PMID:15695376.
21. Vergez S, Delord JP, Thomas F, Rochaix P, Caselles O, Filleron T, et al. Preclinical and clinical evidence that Deoxy-2-[18F]fluoro-D-glucose positron emission tomography with computed tomography is a reliable tool for the detection of early molecular responses to erlotinib in head and neck cancer. Clin Cancer Res 2010; 16:4434-45; PMID:20660574; http://dx.doi.org/10.1158/1078- 0432.CCR-09-2795.
22. Orcutt KP, Parsons AD, Sibenaller ZA, Scarbrough PM, Zhu Y, Sobhakumari A, et al. Erlotinib-mediated inhibition of EGFR signaling induces metabolic oxidative stress through NOX4. Cancer Res 2011; 71:3932-40; PMID:21482679; http://dx.doi.org/10.1158/0008-5472.CAN-10-3425.
23. Qian X, Li J, Ding J, Wang Z, Zhang W, Hu G. Erlotinib activates mitochondrial death pathways related to the production of reactive oxygen species in the human non-small cell lung cancer cell line A549. Clin Exp Pharmacol Physiol 2009; 36:487-94; PMID:19673930; http://dx.doi.org/10.1111/j. 1440-681.2008.05091.x.
24. Eimer S, Belaud-Rotureau MA, Airiau K, Jeanneteau M, Laharanne E, Véron N, et al. Autophagy inhibition cooperates with erlotinib to induce glioblastoma cell death. Cancer Biol Ther 2011; 11:1017-27; PMID:21508666; http://dx.doi.org/10.4161/cbt.11.12.15693.
25. Canel M, Secades P, Rodrigo JP, Cabanillas R, Herrero A, Suarez C, et al. Overexpression of focal adhesion kinase in head and neck squamous cell carcinoma is independent of fak gene copy number. Clin Cancer Res 2006; 12:3272-9; PMID:16740747; http://dx.doi.org/10.1158/1078-0432.CCR-05-1583.
26. Li C, Iida M, Dunn EF, Wheeler DL. Dasatinib blocks cetuximab- and radiation-induced nuclear translocation of the epidermal growth factor receptor in head and neck squamous cell carcinoma. Radiother Oncol 2010; 97:330-7; PMID:20667610; http://dx.doi.org/10.1016/j.radonc.2010.06.010.
27. Milano V, Piao Y, LaFortune T, de Groot J. Dasatinib-induced autophagy is enhanced in combination with temozolomide in glioma. Mol Cancer Ther 2009; 8:394-406; PMID:19190119; http://dx.doi.org/10.1158/1535-7163.MCT-08-0669.
28. Amrein L, Soulières D, Johnston JB, Aloyz R. p53 and autophagy contribute to dasatinib resistance in primary CLL lymphocytes. Leuk Res 2011; 35:99-102; PMID:20573397; http://dx.doi.org/10.1016/j.leukres.2010.05.029.
29. Le XF, Mao W, Lu Z, Carter BZ, Bast RC Jr. Dasatinib induces autophagic cell death in human ovarian cancer. Cancer 2010; 116:4980-90; PMID:20629079; http://dx.doi.org/10.1002/cncr.25426.
30. Yeatman TJ. A renaissance for SRC. Nat Rev Cancer 2004; 4:470-80; PMID:15170449; http://dx.doi.org/10.1038/nrc1366.
31. Summy JM, Gallick GE. Treatment for advanced tumors: SRC reclaims center stage. Clin Cancer Res 2006; 12:1398-401; PMID:16533761; http://dx.doi.org/10. 1158/1078-0432.CCR-05-2692.
32. Ammer AG, Kelley LC, Hayes KE, Evans JV, Lopez-Skinner LA, Martin KH, et al. Saracatinib impairs head and neck squamous cell carcinoma invasion by disrupting invadopodia function. J Cancer Sci Ther 2009; 1:52-61; PMID:20505783; http://dx.doi.org/10.4172/1948-5956.1000009.
33. Chang YM, Bai L, Liu S, Yang JC, Kung HJ, Evans CP. Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530. Oncogene 2008; 27:6365-75; PMID:18679417; http://dx.doi.org/10.1038/onc.2008. 250.
34. Wu Z, Chang PC, Yang JC, Chu CY, Wang LY, Chen NT, et al. Autophagy blockade sensitizes prostate cancer cells towards Src family kinase inhibitors. Genes Cancer 2010; 1:40-9; PMID:20811583; http://dx.doi.org/10.1177/ 1947601909358324.
35. Mehra R, Serebriiskii IG, Dunbrack RL Jr, Robinson MK, Burtness B, Golemis EA. Protein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancer. Drug Resist Updat 2011; 14:260-79; PMID:21920801; http://dx.doi.org/10.1016/j.drup.2011.08. 002.
36. Tejani MA, Cohen RB, Mehra R. The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancer. Biologics 2010; 4:173-85; PMID:20714355.
37. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 359:1116-27; PMID:18784101; http://dx.doi.org/10.1056/NEJMoa0802656.
38. Li X, Fan Z. The epidermal growth factor receptor antibody cetuximab induces autophagy in cancer cells by downregulating HIF-1α and Bcl-2 and activating the beclin 1/hVps34 complex. Cancer Res 2010; 70:5942-52; PMID:20634405; http://dx.doi.org/10.1158/0008-5472.CAN-10-0157.
39. Li X, Lu Y, Pan T, Fan Z. Roles of autophagy in cetuximab-mediated cancer therapy against EGFR. Autophagy 2010; 6:1066-77; PMID:20864811; http://dx.doi.org/10.4161/auto.6.8.13366.
40. Trisciuoglio D, Gabellini C, Desideri M, Ziparo E, Zupi G, Del Bufalo D. Bcl-2 regulates HIF-1α protein stabilization in hypoxic melanoma cells via the molecular chaperone HSP90. PLoS One 2010; 5:11772; PMID:20668552; http://dx.doi.org/10.1371/journal.pone.0011772.
41. Foon KA, Yang XD, Weiner LM, Belldegrun AS, Figlin RA, Crawford J, et al. Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int J Radiat Oncol Biol Phys 2004; 58:984-90; PMID:14967460; http://dx.doi.org/10.1016/j.ijrobp.2003.09.098.
42. Kruser TJ, Armstrong EA, Ghia AJ, Huang S, Wheeler DL, Radinsky R, et al. Augmentation of radiation response by panitumumab in models of upper aerodigestive tract cancer. Int J Radiat Oncol Biol Phys 2008; 72:534-42; PMID:18793955; http://dx.doi.org/10.1016/j.ijrobp.2008.06.1490.
43. Song JI, Grandis JR. STAT signaling in head and neck cancer. Oncogene 2000; 19:2489-95; PMID:10851047; http://dx.doi.org/10.1038/sj.onc.1203483.
44. Giannopoulou E, Antonacopoulou A, Matsouka P, Kalofonos HP. Autophagy: novel action of panitumumab in colon cancer. Anticancer Res 2009; 29:5077-82; PMID:20044619.
45. Chow LQ, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol 2007; 25:884-96; PMID:17327610; http://dx.doi.org/10. 1200/JCO.2006.06.3602.
46. Machiels JP, Henry S, Zanetta S, Kaminsky MC, Michoux N, Rommel D, et al. Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01. J Clin Oncol 2010; 28:21-8; PMID:19917865; http://dx.doi.org/10.1200/JCO.2009.23.8584.
47. Saito Y, Tanaka Y, Aita Y, Ishii KA, Ikeda T, Isobe K, et al. Sunitinib induces apoptosis in pheochromocytoma tumor cells by inhibiting VEGFR2/Akt/mTOR/S6K1 pathways through modulation of Bcl-2 and BAD. Am J Physiol Endocrinol Metab 2012; 302:615-25; PMID:21878661; http://dx.doi.org/10.1152/ ajpendo.00035.2011.
48. Zhao Y, Xue T, Yang X, Zhu H, Ding X, Lou L, et al. Autophagy plays an important role in sunitinib-mediated cell death in H9c2 cardiac muscle cells. Toxicol Appl Pharmacol 2010; 248:20-7; PMID:20637791; http://dx.doi.org/10.1016/ j.taap.2010.07.007.
49. Cohen EE. Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2006; 24:2659-65; PMID:16763280; http://dx.doi.org/10.1200/JCO.2005.05.4577.
50. Williamson SK, Moon J, Huang CH, Guaglianone PP, LeBlanc M, Wolf GT, et al. Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group Study S0420. J Clin Oncol 2010; 28:3330-5; PMID:20498388; http://dx.doi.org/10.1200/JCO.2009.25. 6834.
51. Bareford MD, Park MA, Yacoub A, Hamed HA, Tang Y, Cruickshanks N, et al. Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells. Cancer Res 2011; 71:4955-67; PMID:21622715; http://dx.doi.org/10.1158/0008-5472.CAN-11-0898.
52. Shi YH, Ding ZB, Zhou J, Hui B, Shi GM, Ke AW, et al. Targeting autophagy enhances sorafenib lethality for hepatocellular carcinoma via ER stress-related apoptosis. Autophagy 2011; 7:1159-72; PMID:21691147; http://dx.doi.org/10.4161/ auto.7.10.16818.
53. Park MA, Reinehr R, Häussinger D, Voelkel-Johnson C, Ogretmen B, Yacoub A, et al. Sorafenib activates CD95 and promotes autophagy and cell death via Src family kinases in gastrointestinal tumor cells. Mol Cancer Ther 2010; 9:2220-31; PMID:20682655; http://dx.doi.org/10.1158/1535-7163.MCT-10-0274.
54. Shewchuk L, Hassell A, Wisely B, Rocque W, Holmes W, Veal J, et al. Binding mode of the 4-anilinoquinazoline class of protein kinase inhibitor: X-ray crystallographic studies of 4-anilinoquinazolines bound to cyclin-dependent kinase 2 and p38 kinase. J Med Chem 2000; 43:133-8; PMID:10633045; http://dx.doi.org/10.1021/jm990401t.
55. Del Campo JM, Hitt R, Sebastian P, Carracedo C, Lokanatha D, Bourhis J, et al. Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck. Br J Cancer 2011; 105:618-27; PMID:21829197; http://dx.doi.org/ 10.1038/bjc.2011.237.
56. Tanizaki J, Okamoto I, Fumita S, Okamoto W, Nishio K, Nakagawa K. Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification. Oncogene 2011; 30:4097-106; PMID:21499301; http://dx.doi.org/10.1038/onc.2011.111.
57. Chen S, Li X, Feng J, Chang Y, Wang Z, Wen A. Autophagy facilitates the Lapatinib resistance of HER2 positive breast cancer cells. Med Hypotheses 2011; 77:206-8; PMID:21570197; http://dx.doi.org/10.1016/j.mehy.2011.04.013.
58. Ishii Y, Waxman S, Germain D. Targeting the ubiquitin-proteasome pathway in cancer therapy. Anticancer Agents Med Chem 2007; 7:359-65; PMID:17504161; http://dx.doi.org/10.2174/187152007780618180.
59. Chung CH, Aulino J, Muldowney NJ, Hatakeyama H, Baumann J, Burkey B, et al. Nuclear factorkappaB pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol 2010; 21:864-70; PMID:19850643; http://dx.doi.org/10.1093/annonc/mdp390.
60. Argiris A, Duffy AG, Kummar S, Simone NL, Arai Y, Kim SW, et al. Early tumor progression associated with enhanced EGFR signaling with bortezomib, cetuximab and radiotherapy for head and neck cancer. Clin Cancer Res 2011; 17:5755-64; PMID:21750205; http://dx.doi.org/10.1158/1078-0432.CCR-11-0861.
61. Fribley A, Zeng Q, Wang CY. Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells. Mol Cell Biol 2004; 24:9695-704; PMID:15509775; http://dx.doi.org/10.1128/MCB.24.22.9695-704.2004.
62. Li C, Johnson DE. Bortezomib induces autophagy in head and neck squamous cell carcinoma cells via JNK activation. Cancer Lett 2012; 314:102-7; PMID:21993018; http://dx.doi.org/10.1016/j.canlet.2011.09.020.
63. Molinolo AA, Hewitt SM, Amornphimoltham P, Keelawat S, Rangdaeng S, Meneses García A, et al. Dissecting the Akt/mammalian target of rapamycin signaling network: emerging results from the head and neck cancer tissue array initiative. Clin Cancer Res 2007; 13:4964-73; PMID:17785546; http://dx.doi.org/10.1158/1078-0432.CCR-07-1041.
64. Aissat N, Le Tourneau C, Ghoul A, Serova M, Bieche I, Lokiec F, et al. Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines. Cancer Chemother Pharmacol 2008; 62:305-13; PMID:17912526; http://dx.doi.org/10.1007/s00280-007- 0609-2.
65. Amornphimoltham P, Patel V, Leelahavanichkul K, Abraham RT, Gutkind JS. A retroinhibition approach reveals a tumor cell-autonomous response to rapamycin in head and neck cancer. Cancer Res 2008; 68:1144-53; PMID:18281490; http://dx.doi.org/10.1158/0008-5472.CAN-07-1756.
66. Castedo M, Ferri KF, Kroemer G. Mammalian target of rapamycin (mTOR): pro- and anti-apoptotic. Cell Death Differ 2002; 9:99-100; PMID:11840159; http://dx.doi.org/10.1038/sj.cdd.4400978.
67. Iwamaru A, Kondo Y, Iwado E, Aoki H, Fujiwara K, Yokoyama T, et al. Silencing mammalian target of rapamycin signaling by small interfering RNA enhances rapamycin-induced autophagy in malignant glioma cells. Oncogene 2007; 26:1840-51; PMID:17001313; http://dx.doi.org/10.1038/sj.onc.1209992.
68. Amornphimoltham P, Patel V, Sodhi A, Nikitakis NG, Sauk JJ, Sausville EA, et al. Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck. Cancer Res 2005; 65:9953-61; PMID:16267020; http://dx.doi.org/10.1158/0008-5472.CAN-05-0921.
69. Patel V, Marsh CA, Dorsam RT, Mikelis CM, Masedunskas A, Amornphimoltham P, et al. Decreased lymphangiogenesis and lymph node metastasis by mTOR inhibition in head and neck cancer. Cancer Res 2011; 71:7103-12; PMID:21975930; http://dx.doi.org/10.1158/0008-5472.CAN-10-3192.
70. Lin CI, Whang EE, Donner DB, Du J, Lorch J, He F, et al. Autophagy induction with RAD001 enhances chemosensitivity and radiosensitivity through Met inhibition in papillary thyroid cancer. Mol Cancer Res 2010; 8:1217-26; PMID:20736296; http://dx.doi.org/10.1158/1541-7786.MCR-10-0162.
71. Bozec A, Etienne-Grimaldi MC, Fischel JL, Sudaka A, Toussan N, Formento P, et al. The mTOR-targeting drug temsirolimus enhances the growth-inhibiting effects of the cetuximab-bevacizumab-irradiation combination on head and neck cancer xenografts. Oral Oncol 2011; 47:340-4; PMID:21421338; http://dx.doi.org/10.1016/j.oraloncology.2011.02.020.
72. Ekshyyan O, Rong Y, Rong X, Pattani KM, Abreo F, Caldito G, et al. Comparison of radiosensitizing effects of the mammalian target of rapamycin inhibitor CCI-779 to cisplatin in experimental models of head and neck squamous cell carcinoma. Mol Cancer Ther 2009; 8:2255-65; PMID:19625495; http://dx.doi.org/10.1158/1535-7163.MCT-08-1184.
73. Yazbeck VY, Buglio D, Georgakis GV, Li Y, Iwado E, Romaguera JE, et al. Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma. Exp Hematol 2008; 36:443-50; PMID:18343280; http://dx.doi.org/10.1016/j.exphem.2007.12.008.
74. Klos KS, Wyszomierski SL, Sun M, Tan M, Zhou X, Li P, et al. ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells. Cancer Res 2006; 66:2028-37; PMID:16489002; http://dx.doi.org/10.1158/0008-5472.CAN-04-4559.
75. Kamal A, Boehm MF, Burrows FJ. Therapeutic and diagnostic implications of Hsp90 activation. Trends Mol Med 2004; 10:283-90; PMID:15177193; http://dx.doi.org/10.1016/j.molmed.2004.04.006.
76. Zhang H, Burrows F. Targeting multiple signal transduction pathways through inhibition of Hsp90. J Mol Med (Berl) 2004; 82:488-99; PMID:15168026; http://dx.doi.org/10.1007/s00109-004-0549-9.
77. Brandt GE, Blagg BS. Alternate strategies of Hsp90 modulation for the treatment of cancer and other diseases. Curr Top Med Chem 2009; 9:1447-61; PMID:19860731; http://dx.doi.org/10.2174/156802609789895683.
78. Cohen SM, Mukerji R, Samadi AK, Zhao H, Blagg BS, Cohen MS. Novel C-terminal Hsp90 inhibitor for head and neck squamous cell cancer (HNSCC) with in vivo efficacy and improved toxicity profiles compared with standard agents. Ann Surg Oncol 2011; PMID:21837531; http://dx.doi.org/10.1245/s10434-011-1971-1.
79. Yin X, Zhang H, Burrows F, Zhang L, Shores CG. Potent activity of a novel dimeric heat shock protein 90 inhibitor against head and neck squamous cell carcinoma in vitro and in vivo. Clin Cancer Res 2005; 11:3889-96; PMID:15897590; http://dx.doi.org/10.1158/1078-0432.CCR-04-2272.
80. Qing G, Yan P, Qu Z, Liu H, Xiao G. Hsp90 regulates processing of NFκB2 p100 involving protection of NFκB-inducing kinase (NIK) from autophagy-mediated degradation. Cell Res 2007; 17:520-30; PMID:17563756; http://dx.doi.org/10.1038/cr.2007.47.
81. Copetti T, Demarchi F, Schneider C. p65/RelA binds and activates the beclin 1 promoter. Autophagy 2009; 5:858-9; PMID:19458474.
82. Jiang Q, Wang Y, Li T, Shi K, Li Z, Ma Y, et al. Heat shock protein 90-mediated inactivation of nuclear factorκB switches autophagy to apoptosis through becn1 transcriptional inhibition in selenite-induced NB4 cells. Mol Biol Cell 2011; 22:1167-80; PMID:21346199; http://dx.doi.org/10.1091/ mbc.E10-10-0860.
83. Weichert W. HDAC expression and clinical prognosis in human malignancies. Cancer Lett 2009; 280:168-76; PMID:19103471; http://dx.doi.org/10.1016/j. canlet.2008.10.047.
84. Chang HH, Chiang CP, Hung HC, Lin CY, Deng YT, Kuo MY. Histone deacetylase 2 expression predicts poorer prognosis in oral cancer patients. Oral Oncol 2009; 45:610-4; PMID:18951835; http://dx.doi.org/10.1016/j.oraloncology. 2008.08.011.
85. Iglesias-Linares A, Yañez-Vico RM, González-Moles MA. Potential role of HDAC inhibitors in cancer therapy: insights into oral squamous cell carcinoma. Oral Oncol 2010; 46:323-9; PMID:20207580; http://dx.doi.org/10. 1016/j.oraloncology.2010.01.009.
86. Erjala K, Sundvall M, Junttila TT, Zhang N, Savisalo M, Mali P, et al. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells. Clin Cancer Res 2006; 12:4103-11; PMID:16818711; http://dx.doi.org/10.1158/1078-0432.CCR-05-2404.
87. Han JW, Ahn SH, Park SH, Wang SY, Bae GU, Seo DW, et al. Apicidin, a histone deacetylase inhibitor, inhibits proliferation of tumor cells via induction of p21WAF1/Cip1 and gelsolin. Cancer Res 2000; 60:6068-74; PMID:11085529.
88. Liu YL, Yang PM, Shun CT, Wu MS, Weng JR, Chen CC. Autophagy potentiates the anti-cancer effects of the histone deacetylase inhibitors in hepatocellular carcinoma. Autophagy 2010; 6:1057-65; PMID:20962572; http://dx.doi.org/10.4161/ auto.6.8.13365.
89. Ahn MY, Ahn SG, Yoon JH. Apicidin, a histone deaceylase inhibitor, induces both apoptosis and autophagy in human oral squamous carcinoma cells. Oral Oncol 2011; 47:1032-8; PMID:21856210; http://dx.doi.org/10.1016/j. oraloncology.2011.07.027.